Invivyd, Inc. (IVVD) Stock Score, Valuation & Financial Research

Invivyd, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for IVVD

Invivyd, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.81. These figures are a research snapshot, not a buy or sell recommendation.

What Invivyd, Inc. does

Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Invivyd is a biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapies for serious viral diseases. The company utilizes a proprietary integrated technology platform to engineer monoclonal antibodies, aiming to generate revenue through the commercialization of authorized products like PEMGARDA and future product candidates, while currently relying on external capital to fund its research and development operations.

Products and services

  • The company's primary product is PEMGARDA (pemivibart), a monoclonal antibody authorized for emergency use in the U.S. for COVID-19 prevention. Its pipeline includes VYD2311, a clinical-stage monoclonal antibody candidate for COVID-19, and VMS063, a preclinical candidate targeting measles.

Brands and product families

  • PEMGARDA — The company's only authorized product for the prevention of COVID-19. Source

Annual revenue by business

  • Product: USD 53,426,000 · 100.00% calculated revenue share (period 2025-12-31) Source

Revenue share is not a unit-sales or best-seller ranking. Categories may overlap; do not add rows from different breakdowns.

Customer types

Healthcare providers and patients requiring COVID-19 prevention.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on unnamed third-party contract manufacturing organizations for the production of its product candidates and commercial supplies. Source

Business strengths to evaluate

  • Proprietary integrated antibody discovery and engineering technology platform Source

Business risks and research considerations

  • Substantial doubt regarding ability to continue as a going concern Source
  • High dependency on the commercial success of a single authorized product, PEMGARDA Source
  • Need for additional funding to support continuing operations Source

Sources: Company research source · Product

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

IVVD financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.81
Market capitalization:
237.57M (currency not supplied)
Revenue:
USD 58.37M
Net income:
USD -107.33M
Free cash flow:
USD -58.29M
Cash:
USD 160.08M
Total debt:
USD 8.39M
EPS:
USD -0.39

What stands out

  • Reported year-over-year revenue growth is +9.2%.
  • Free cash flow is USD -58.29M, negative for the stored period.
  • The balance sheet shows USD 160.08M of cash versus USD 8.39M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -99.9% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -183.9% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 151.69M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for IVVD

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can IVVD maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • How long can IVVD fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is IVVD likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for IVVD to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of IVVD's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research IVVD

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.